4503.T) announced today that the primary endpoint of its Phase III PASHA trial evaluating XOSPATA">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from Astellas Pharma Inc. was processed by Pulse News Wire on March 9, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Astellas Pharma's Phase III PASHA Trial for XOSPATA Fails Primary Endpoint

TOKYO, Mar 09 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) announced today that the primary endpoint of its Phase III PASHA trial evaluating XOSPATA (gilteritinib) against midostaurin in untreate

View all 4503.T disclosures →

Share this disclosure: Share on X Share on LinkedIn